Precision BioSciences Announces CEO Transition Plan
April 06, 2021 08:35 ET
|
Precision Biosciences
DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day
March 29, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
March 18, 2021 07:00 ET
|
Precision Biosciences
Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by...
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
March 12, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year...
Precision BioSciences to Present at Upcoming Virtual Investor Conferences
March 02, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates
February 19, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy...
Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
February 04, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome...
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
January 25, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS®...
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
January 19, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS®...
Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company
January 07, 2021 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...